Call for Speakers...

9th World Congress on Breast Cancer and Therapies
#April 29-30, 2019
#Kyoto #Japan
Theme: Advancement in Breast Cancer and Helping at Every Step of the Journey

Speaker slots available
Choose your track

• Types of Breast Cancer
• Reconstruction of Breast cancer
• Treating Breast Cancer With Chemotherapy
• Treatment & Side Effects of Breast Cancer
• Surgeries involved in Breast Cancer
• Breast Cancer: Clinical Trials
• Breast Cancer Risk and Prevention
• Breast Cancer Nursing
• Male Breast Cancer Research
• Clinical Staging of Breast Cancer
• Breast Cancer Radiation Therapy
• Breast Cancer during Pregnancy
• Breast Cancer Therapies
• Mastectomy

Submit your abstract,

Get registered

#confirmslot

Womens Day : Special Discount...

                          9th World Congress on Breast Cancer and Therapies

#April 29-30, 2019
#Kyoto #Japan

Theme: "Advancement in breast cancer and Helping at every step of the journey"

#Breast Cancer summit 2019 aims to provide optimal health and healthcare to adolescent girls and women, with focus on the prevention, diagnosis of Breast Cancer, as well as related Genetics, Pathophysiology, Epidemiology, Clinical Reports etc.

Women's Day special discount 30% on all registration prices
#discount #women'day #30%
#registersoon #delegate #speaker
#YRF #workshop #exhibition

Ductal Carcinoma In Situ (DCIS)

Ductal carcinoma in situ (DCIS) is non-invasive breast cancer. Ductal means that cancer starts inside the milk ducts, carcinoma refers to any cancer that begins in the skin or other tissues (including breast tissue) that cover or line the internal organs, and in situ means "in its original place." DCIS is called "non-invasive" because it hasn’t spread beyond the milk duct into any normal surrounding breast tissue. DCIS isn’t life-threatening, but having DCIS can increase the risk of developing invasive breast cancer later on.

When you have had DCIS, you are at higher risk for cancer coming back or for developing new breast cancer than a person who has never had breast cancer before. Most recurrences happen within the 5 to 10 years after initial diagnosis. The chances of a recurrence are under 30%.

Women who have breast-conserving surgery (lumpectomy) fLower Your Risk section. If breast cancer does come back after earlier DCIS treatment, the recurrence is non-invasive (DCIS again) about half the time and invasive about half the time. DCIS itself is NOT invasive.

or DCIS without radiation therapy has about a 25% to 30% chance of having a recurrence at some point in the future. Including radiation therapy in the treatment plan after surgery drops the risk of recurrence to about 15%. Learn what additional steps you can take to lower your risk of a new breast cancer diagnosis or a recurrence in the

There are two main reasons this number is so large and has been increasing over time:

• People are living much longer lives. As we grow older, our risk of breast cancer increases.
• More people are getting mammograms, and the quality of the mammograms has improved. With better screening, more cancers are being spotted early.

#AbstractSubmission hashtag#breastcancersummit2019 hashtag#Sep11-12,2019. Participate Learn Share Research on hashtag#Oncology hashtag#Cancertypes hashtag#Breastcancerprevention hashtag#Cancernursing hashtag#Cancercare hashtag#cancertreatment hashtag#cancerbreastfeeding hashtag#cancerfree etc., hashtag#Submit@#breastcancersummit@cancermeet.org Meet hashtag#professionals hashtag#professors hashtag#youngresearchers hashtag#enterprenuers hashtag#scientists learn more about hashtag#BreastCancer hashtag#Fight & hashtag#Raise your hashtag#voice hashtag#againstCancer. Hope to see you all in hashtag#Japan in the esteemed hashtag#conference. Come join us @Kyoto Japan to fight against Breast cancer.

Phyllodes Tumors of the Breast

#Breast Cancer #types #phyllode #ducts #lobules #Connective_tissue #Biopsy #mammogram #physical_exam #MRI #Ultrasound
Breast cancers called carcinomas, which develop inside the ducts (milk-carrying tubes) or lobules (milk-producing glands) of the breast, phyllodes tumors start outside of the ducts and lobules. Phyllodes tumors develop in the breast's connective tissue, called the stroma. The stroma includes the fatty tissue and ligaments that surround the ducts, lobules, and blood and lymph vessels in the breast. It may be helpful to think of the stroma as the tissue that "holds everything together" inside the breast. In addition to stromal cells, phyllodes tumors can also contain cells from the ducts and lobules.

The most common symptom of a phyllodes tumor is a breast lump that you or your doctor can feel while examining the breasts. Phyllodes tumors tend to grow quickly, within a period of weeks or months, to a size of 2-3 cm or sometimes larger. This rapid growth does not automatically mean the phyllodes tumor is malignant; benign tumors can grow quickly, too. The lump is usually not painful. If left unchecked, the lump can create a visible bulge as it pushes against the skin. In more advanced cases — whether benign, borderline, or malignant — a phyllodes tumor can cause an ulcer or open wound to form on the breast skin.

Paget's Disease of the Nipple

#Cancer # Breast_Cancer #Paget's_disease_Nipple #pain #flattening #yellowish_discharge #Be a part of these Prestigious event with experts #Breast_cancer_summit 2019



Paget's disease of the nipple is a rare form of breast cancer in which cancer cells collect in or around the nipple. Cancer usually affects the ducts of the nipple first (small milk-carrying tubes), then spreads to the nipple surface and the areola (the dark circle of skin around the nipple). The nipple and areola often become scaly, red, itchy, and irritated.
Doctors are not yet completely sure how Paget's disease develops. One possibility is that the cancer cells start growing inside the milk ducts within the breast and then make their way out to the nipple surface. This would appear to explain why so many people with Paget's disease of the nipple have a second area of cancer within the breast. Another theory is that the cells of the nipple itself become cancerous. This theory would explain the small number of people who: (1) only have Paget's disease in the nipple, or (2) have a second breast cancer that appears to be completely separate from the Paget's disease.
Paget's disease of the nipple is more common in women, but like other forms of breast cancer, it can also affect men. The disease usually develops after age 50. According to the National Cancer Institute, the average age of diagnosis in women is 62, and in men, 69. 

Molecular Sub-types of Breast cancer

There are five main intrinsic or molecular subtypes of breast cancer that are based on the genes cancer expresses:

#Cancer #Breast Cancer #types #Subtype #Molecular #Luminal_A #Luminla B #Triple Negative #HER2 Enriched #Normal

• Luminal A breast cancer is hormone-receptor-positive (estrogen-receptor and/or progesterone-receptor positive), HER2 negative, and has low levels of the protein Ki-67, which helps control how fast cancer cells grow. Luminal A cancers are low-grade, tend to grow slowly and have the best prognosis.
• Luminal B breast cancer is hormone-receptor-positive (estrogen-receptor and/or progesterone-receptor positive), and either HER2 positive or HER2 negative with high levels of Ki-67. Luminal B cancers generally grow slightly faster than luminal A cancers and their prognosis is slightly worse.
• Triple-negative/basal-like breast cancer is hormone-receptor-negative (estrogen-receptor and progesterone-receptor negative) and HER2 negative. This type of cancer is more common in women with BRCA1 gene mutations. Researchers aren’t sure why, but this type of cancer also is more common among younger and African-American women.
• HER2-enriched breast cancer is hormone-receptor-negative (estrogen-receptor and progesterone-receptor negative) and HER2 positive. HER2-enriched cancers tend to grow faster than luminal cancers and can have a worse prognosis, but they are often successfully treated with targeted therapies aimed at the HER2 protein.
• Normal-like breast cancer is similar to luminal A disease: hormone-receptor positive (estrogen-receptor and/or progesterone-receptor positive), HER2 negative, and has low levels of the protein Ki-67, which helps control how fast cancer cells grow. Still, while normal-like breast cancer has a good prognosis, its prognosis is slightly worse than luminal A cancer’s prognosis.